Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03243305 · ClinicalTrials.gov registry record · Phase 3
AMP002 Phase III Contraceptive Study
A Phase 3 study, sponsored by Evofem.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,384
- Enrollment target
NCT03243305 is a Phase 3 study that has completed, run by Evofem. The registered enrollment target is 1,384 participants.
The verdict
NCT03243305, a Phase 3 study, has completed, sponsored by Evofem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,384 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
Interventions
- DRUG AMPHORA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,384 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2018-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03243305
The ClinicalTrials.gov registry entry for NCT03243305 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evofem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMPHORA is the first listed.
NCT03243305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03243305 about?
NCT03243305 is a clinical study titled "AMP002 Phase III Contraceptive Study". This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
What is the current status of trial NCT03243305?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,384 participants. The study started on 2017-07-24. Estimated completion is 2018-11-29.
What interventions are being tested in trial NCT03243305?
The interventions under investigation include: AMPHORA (DRUG).
Who is sponsoring clinical trial NCT03243305?
This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.